Dr. Danielle Janosevic is a board-certified nephrologist, physician-scientist, and Assistant Professor of Medicine at the Indiana University School of Medicine. She is dedicated to advancing precision medicine in nephrology through translational research that bridges molecular discovery with clinical care. Following completion of her medical degree at New York Institute of Technology College of Osteopathic Medicine (NYITCOM), she completed the ABIM research pathway in internal medicine and nephrology at Indiana University, where she established an interdisciplinary research program integrating clinical nephrology with bioinformatics, and systems biology.

Dr. Janosevic's research focuses on understanding the molecular mechanisms that drive acute kidney injury (AKI), kidney repair, and progression to chronic kidney disease. Her laboratory employs cutting-edge multiomic technologies to define the cellular and molecular pathways that regulate kidney injury and recovery. By integrating multiomic analyses with human biospecimens and experimental models, her work seeks to identify novel biomarkers and therapeutic targets that improve the diagnosis, risk stratification, and treatment of kidney disease.

A major focus of her research is the development of minimally invasive molecular biomarkers that reflect the biological state of the injured kidney and enable precision diagnosis of AKI. Her current work investigates transcriptomic and proteomic signatures in blood and kidney tissue to improve early detection of kidney injury, predict recovery, and identify patients most likely to benefit from targeted therapies.

Dr. Janosevic has authored numerous peer-reviewed publications in leading nephrology and biomedical journals and has received competitive federal and foundation funding to support her research. Her work has advanced the understanding of cellular heterogeneity and dynamic molecular responses underlying kidney injury and repair. As a physician-scientist, her long-term goal is to translate discoveries from genomics and molecular medicine into clinically actionable diagnostic tools and therapeutic strategies that improve outcomes for patients with kidney disease and transform the practice of precision nephrology.